blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4003291

EP4003291 - OPHTHALMIC COMPOSITIONS COMPRISING VISCOSIFYING POLYMERS AND NUCLEIC ACIDS [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  19.04.2024
Database last updated on 07.10.2024
FormerRequest for examination was made
Status updated on  29.04.2022
FormerThe international publication has been made
Status updated on  05.02.2021
Formerunknown
Status updated on  30.07.2020
Most recent event   Tooltip19.04.2024Withdrawal of applicationpublished on 22.05.2024  [2024/21]
Applicant(s)For all designated states
ProQR Therapeutics II B.V.
Zernikedreef 9
2333 CK Leiden / NL
[2022/22]
Inventor(s)01 / PLATENBURG, Gerardus Johannes
Zernikedreef 9
2333 CK Leiden / NL
02 / VAN MIERLO, Elisabeth Laurentina Wilhelmina Maria
Zernikedreef 9
2333 CK Leiden / NL
03 / YILMAZ-ELIS, Aliye Seda
Zernikedreef 9
2333 CK Leiden / NL
 [2022/22]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
[2022/22]
Application number, filing date20743148.724.07.2020
[2022/22]
WO2020EP70897
Priority number, dateEP2019018868126.07.2019         Original published format: EP 19188681
EP2019019864220.09.2019         Original published format: EP 19198642
[2022/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021018750
Date:04.02.2021
Language:EN
[2021/05]
Type: A1 Application with search report 
No.:EP4003291
Date:01.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 04.02.2021 takes the place of the publication of the European patent application.
[2022/22]
Search report(s)International search report - published on:EP04.02.2021
ClassificationIPC:A61K9/00, A61K38/00, A61K9/06, A61K47/10, A61K47/38
[2022/22]
CPC:
A61K9/0048 (EP,IL,US); A61K31/7088 (EP,IL,US); A61K47/38 (EP,IL,US);
A61K9/06 (EP,IL)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/22]
TitleGerman:OPHTHALMISCHE ZUSAMMENSETZUNGEN MIT VISKOSITÄTSERHÖHENDEN POLYMEREN UND NUKLEINSÄUREN[2022/22]
English:OPHTHALMIC COMPOSITIONS COMPRISING VISCOSIFYING POLYMERS AND NUCLEIC ACIDS[2022/22]
French:COMPOSITIONS OPHTALMIQUES COMPRENANT DES POLYMÈRES VISCOSIFIANTS ET DES ACIDES NUCLÉIQUES[2022/22]
Entry into regional phase22.02.2022National basic fee paid 
22.02.2022Designation fee(s) paid 
22.02.2022Examination fee paid 
Examination procedure22.02.2022Examination requested  [2022/22]
22.02.2022Date on which the examining division has become responsible
11.10.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
11.10.2022Despatch of communication of loss of particular rights: Claims {1}
20.12.2022Amendment by applicant (claims and/or description)
15.04.2024Application withdrawn by applicant  [2024/21]
Request for further processing for:20.12.2022Request for further processing filed
20.12.2022Full payment received (date of receipt of payment)
Request granted
05.01.2023Decision despatched
Fees paidRenewal fee
27.07.2022Renewal fee patent year 03
27.07.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO9424983  (RIBOZYME PHARM INC [US]) [X] 1-11 * claims 1-7 * * figure 5 *;
 [X]EP1625851  (BBK BIO CORP [JP]) [X] 1-11* paragraph [0118] - paragraph [0213] *;
 [X]WO2014025792  (BAYLOR COLLEGE MEDICINE [US], et al) [X] 1-17 * claims 1-27 *;
 [X]  - BOCHOT A ET AL, "Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms", JOURNAL OF DRUG TARGETING, TAYLOR & FRANCIS, GB, (19980101), vol. 6, no. 4, ISSN 1061-186X, pages 309 - 313, XP008126963 [X] 1-17 * page 310, column l, line 1 - page 310, column l, line 63 *
by applicantWO2004108945
 US2009163432
 EP2049664
 WO2011140194
 WO2012136969
 WO2014025792
 WO2014039012
 WO2016005514
 EP2526923
 WO2017060317
 WO2017186739
 WO2018055134
    - MOISEEV et al., "Penetration enhancers in ocular drug delivery", Pharmaceutics, (20190000), vol. 11, page 321
    - BOCHOT et al., "Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms", J Drug Targeting, (19980000), vol. 6, no. 4, pages 309 - 313, XP008126963
    - JOHNSON LN. et al., "Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea", Mol Ther, (20180000), vol. 16, no. 1, doi:10.1038/SJ.MT.6300324, pages 107 - 114, XP002521463

DOI:   http://dx.doi.org/10.1038/SJ.MT.6300324
    - LUDWIG A, "The use of mucoadhesive polymers in ocular drug delivery", Adv Drug Del Rev, (20050000), vol. 57, doi:10.1016/j.addr.2005.07.005, pages 1595 - 1639, XP025284002

DOI:   http://dx.doi.org/10.1016/j.addr.2005.07.005
    - BARATZ KH et al., "E2-2 protein and Fuch's corneal dystrophy", N Engl J Med, (20100000), vol. 363, pages 1016 - 1024
    - SUNDIN OH et al., "A common locus for late onset Fuchs corneal dystrophy maps to 18q21.2-q21.32", Invest Ophthalmol Vis Sci, (20060000), vol. 47, pages 3919 - 3926
    - WIEBEN ED et al., "A common trinucleotide repeat expansion within the transcription 4 (TCF4, E2-2) gene predicts Fuchs corneal dystrophy", PLoS One, (20120000), vol. 7, doi:10.1371/journal.pone.0049083, page e49083, XP055075341

DOI:   http://dx.doi.org/10.1371/journal.pone.0049083
    - WIEBEN ED et al., "Comprehensive assessment of genetic variants within TCF4 in Fuchs' endothelial corneal dystrophy", Invest Ophtalmol Vis Sci, (20140000), vol. 55, pages 6101 - 6107
    - MOOTHA VV et al., "Association and familial segregation of CTG18.1 trinucleotide expansion of TCF4 gene in Fuchs' endothelial corneal dystrophy", Invest Ophtalmol Vis Sci, (20140000), vol. 55, pages 32 - 42
    - STAMLER JF et al., "Confirmation of the association between the TCF4 risk allele and Fuchs endothelial corneal dystrophy in patients from the Midwestern United States", Ophthalmic Genet., (20130000), vol. 34, no. 1-2, pages 32 - 4
    - KUOT A et al., "Association of TCF4 and CLU polymorphisms with Fuchs' endothelial dystrophy and implication of CLU and TGFBI proteins in the disease process", Eur J Hum Genet., (20120000), vol. 20, no. 6, pages 632 - 8
    - THALAMUTHU A et al., "Association of TCF4 gene polymorphisms with Fuchs' corneal dystrophy in the Chinese", Invest Ophthalmol Vis Sci., (20110000), vol. 52, no. 8, pages 5573 - 8
    - XING C et al., "Transethnic replication of association of CTG18.1 repeat expansion of TCF4 gene with Fuchs' corneal dystrophy in Chinese implies common causal variant", Invest Ophthalmol Vis Sci., (20140000), vol. 55, no. 11, pages 7073 - 8
    - NANDA GG et al., "Genetic association of TCF4 intronic polymorphisms, CTG18.1 and rs17089887, with Fuchs' endothelial corneal dystrophy in an Indian population", Invest Ophthalmol Vis Sci., (20140000), vol. 55, no. 11, pages 7674 - 80
    - DU et al., "RNA toxicity and missplicing in the common eye disease Fuch's endothelial corneal dystrophy", J Biol Chem, (20150000), vol. 290, no. 10, doi:10.1074/jbc.M114.621607, pages 5979 - 90, XP055328238

DOI:   http://dx.doi.org/10.1074/jbc.M114.621607
    - MULDERS et al., "Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy", Proc Natl Acad Sci USA, (20090000), vol. 106, no. 33, doi:10.1073/pnas.0905780106, pages 13915 - 20, XP055007026

DOI:   http://dx.doi.org/10.1073/pnas.0905780106
    - WINCHESTER CL et al., "Characterization of the expression of DMPK and SIX5 in the human eye and implications of pathogenesis in myotonic dystrophy", Hum Mol Genet., (19990000), vol. 8, pages 481 - 492
    - GATTEY D et al., "Fuchs endothelial corneal dystrophy in patients with myotonic dystrophy: a case series", Cornea, (20140000), vol. 33, pages 96 - 98
    - NIELSEN et al., Science, (19910000), vol. 254, pages 1497 - 1500
    - GOVINDARAJUKUMAR, Chem Commun, (20050000), pages 495 - 497
    - EGHOLM et al., Nature, (19930000), vol. 365, pages 566 - 568
    - MORITA et al., Nucleic Acid Res Supplement, (20010000), vol. 1, pages 241 - 242
    - HAGHIGHAT JAHROMI A et al., "Developing bivalent ligands to target CUG triplet repeats, the causative agent of Myotonic Dystrophy Type 1", J Med Chem, (20130000), vol. 56, pages 9471 - 9481
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.